Richard Paulson is the President and CEO of Karyopharm Therapeutics, a biopharmaceutical company focused on developing novel cancer therapies. With over 25 years of experience in the industry, Paulson has held significant leadership roles at Ipsen Pharmaceuticals and Amgen. His extensive background in oncology and global product commercialization positions him to lead Karyopharm into its next phase of growth and innovation.
Who is the CEO of Karyopharm Therapeutics?
Richard Paulson, the CEO of Karyopharm Therapeutics, brings a wealth of experience from his extensive career in the biopharmaceutical industry. Before joining Karyopharm, he held significant leadership roles at Ipsen Pharmaceuticals and Amgen, where he was instrumental in global product commercialization and executive leadership. His career also includes key positions at Pfizer and GlaxoWellcome in Canada.
Work History
Richard Paulson's extensive career in the biopharmaceutical industry includes a variety of leadership roles at several prominent companies. Here is a detailed list of his work history:
Education History
Richard Paulson's educational background is rooted in a strong foundation of business and management. He earned his MBA from the University of Toronto's Rotman School of Management, where he completed the Executive MBA program between 1994 and 1996. Prior to that, Paulson obtained a Bachelor of Commerce degree in Marketing and Finance from the University of Saskatchewan, graduating in 1989. This combination of advanced business education and specialized undergraduate studies has equipped him with the knowledge and skills essential for his leadership roles in the biopharmaceutical industry.
When did Richard Paulson join Karyopharm Therapeutics?
Richard Paulson joined Karyopharm Therapeutics' Board of Directors in February 2020 and was appointed President and Chief Executive Officer on May 3, 2021. As of 2023, he has been with the company for approximately three years, with two of those years spent in his current role as CEO. His leadership is expected to drive the company's growth and innovation in developing novel cancer therapies.